The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia

Bone Research

Volumn 4, Issue , 2016, Pages

  Zhang, Qian ^a   Doucet, Michele ^a   Tomlinson, Ryan E ^a   Han, Xiaobin ^b   Quarles, L Darryl ^c   Collins, Michael T ^c   Clemens, Thomas L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MIMOSINE; PHOSPHATE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BONE PAIN; CANCER SURGERY; CASE REPORT; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CULTURE MEDIUM; FEMALE; FRACTURE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MIDDLE AGED; ONCOGENIC OSTEOMALACIA; ORGAN CULTURE; OSTEOBLAST; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINDLE CELL; UPREGULATION;

EID: 84979210013     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2016.11     Document Type: Article

References (18)

1. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord 2001; 2: 175-186.
2. Chong WH, Molinolo AA, Chen CC et al. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18: R53-R77.
3. Huang X, Jiang Y, Xia W. FGF23 and phosphate wasting disorders. Bone Res 2013; 1: 120-132.
4. Jiang Y, Xia WB, Xing XP et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 2012; 27: 1967-1975.
5. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 1-30.
6. Weidner N. Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol 1991; 15: 317-333.
7. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086.
8. Farrow EG, White KE. Recent advances in renal phosphate handling. Nat Rev Nephrol 2010; 6: 207-217.
9. Farrow EG, Yu X, Summers LJ et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108: E1146-E1155.
10. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480.
11. Medici D, Olsen BR. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One 2012; 7: e42913.
12. Ji Y, Chen S, Li K et al. Signaling pathways in the development of infantile hemangioma. J Hematol Oncol 2014; 7: 13.
13. Chong WH, Andreopoulou P, Chen CC et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 2013; 28: 1386-1398.
14. Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 2015; 290: 10447-10459.
15. Krishnamachary B, Semenza GL. Analysis of hypoxia-inducible factor 1alpha expression and its effects on invasion and metastasis. Methods Enzymol 2007; 435: 347-354.
16. Zhang H, Qian DZ, Tan YS et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586.
17. Galban S, Gorospe M. Factors interacting with HIF-1alpha mRNA: novel therapeutic targets. Curr Pharm Des 2009; 15: 3853-3860.
18. Lee JC, Jeng YM, Su SY et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 2015; 235: 539-545.